D-Glycerate Dehydrogenase (PHGDH) Deficiency

D-Glycerate dehydrogenase deficiency—also known as 3-phosphoglycerate dehydrogenase (PHGDH) deficiency—is a rare autosomal recessive metabolic disorder in which the enzyme PHGDH is nonfunctional or absent. PHGDH catalyzes the first and committed step of the phosphorylated pathway for synthesizing the amino acid L-serine by converting 3-phosphoglycerate into 3-phosphohydroxypyruvate. Without this enzymatic activity, patients cannot produce sufficient serine in the brain—where dietary serine cannot cross the blood–brain barrier—leading to profound neurologic impairment from infancy onward en.wikipedia.orgmedlineplus.gov.

Clinically, PHGDH deficiency manifests as a spectrum, from the lethal Neu-Laxova syndrome in neonates (characterized by severe edema, ichthyosis, and joint contractures) to milder infantile, juvenile, or even adult forms with variable developmental delay, microcephaly, seizures, and movement disorders en.wikipedia.orgmedlineplus.gov. Treatment hinges on early diagnosis and lifelong oral supplementation with L-serine (and often glycine), which can ameliorate seizures and support neurodevelopment if begun promptly after birth en.wikipedia.org.

---

Types

1. Neu-Laxova Syndrome (Severe Neonatal Form)
   This is the most severe presentation. Affected neonates exhibit fetal hydrops, severe microcephaly, ichthyosis, limb contractures, and often die in utero or shortly after birth. Mutations are typically homozygous null alleles leading to complete loss of PHGDH activity en.wikipedia.org.

2. Infantile Onset (Classic PHGDH Deficiency)
   Infants appear normal at birth but develop congenital microcephaly, psychomotor retardation, and refractory seizures within the first few months. Without treatment, developmental milestones are profoundly delayed en.wikipedia.org.

3. Juvenile Onset (Moderate Form)
   Children present later, often between ages 2–10, with mild to moderate developmental delay, epilepsy, behavioral disorders, and variable intellectual disability. Seizures may be fewer and slower to manifest compared to the infantile form medlineplus.gov.

4. Adult Onset (Rare Mild Phenotype)
   Extremely uncommon; only a handful of cases. Adults develop mild intellectual disability, coordination difficulties (ataxia), and peripheral neuropathy. Residual PHGDH activity from milder missense mutations allows survival into adulthood medlineplus.gov.

---

Causes

All causes stem from genetic alterations that impair PHGDH enzyme function. Below are categories of mutations and genetic risk factors—each leads to deficient serine synthesis:

1. Missense Mutations in PHGDH
   Single amino acid substitutions (e.g., V490M) that reduce enzyme activity by destabilizing the protein structure sciencedirect.com.

2. Nonsense Mutations
   Early stop codons truncate the enzyme, abolishing activity.

3. Frameshift Insertions/Deletions
   Indels shift the reading frame, producing nonfunctional proteins.

4. Splice-Site Mutations
   Alteration of intron–exon boundaries leads to aberrant mRNA splicing and loss of functional enzyme.

5. Deep Intronic Variants
   Noncoding changes create cryptic splice sites or affect gene expression.

6. Promoter Region Mutations
   Disrupt transcription factor binding, reducing PHGDH gene expression.

7. Copy Number Variants (Deletions)
   Large genomic deletions remove one or more PHGDH exons.

8. Compound Heterozygosity
   Two different pathogenic alleles in trans further diminish enzyme function.

9. Homozygosity Due to Consanguinity
   Parental relatedness increases likelihood of inheriting identical PHGDH mutations.

10. Founder Mutations
    Population-specific alleles propagated by a common ancestor.

11. De Novo Mutations
    New variants arising in gametes or early embryogenesis.

12. Germline Mosaicism
    Parental mosaicism yields variable PHGDH expression in offspring.

13. Regulatory Region Variants
    Affect enhancers or repressors controlling PHGDH transcription.

14. Epigenetic Silencing
    Aberrant promoter methylation can inhibit gene expression.

15. Gene Conversion Events
    Nonreciprocal transfer of sequence from a pseudogene disrupts PHGDH.

16. Large Chromosomal Rearrangements
    Translocations or inversions disrupt PHGDH locus integrity.

17. Uniparental Disomy
    Two copies of mutant PHGDH inherited from one parent.

18. Mitochondrial Dysfunction (Secondary)
    Impaired energy metabolism may worsen serine synthetic defects.

19. Nutritional Deficiency (Modifying Factor)
    Severe maternal malnutrition may exacerbate neonatal presentation.

20. Environmental Teratogens (Hypothetical Modifier)
    Though not causal, in utero exposures (e.g., toxins) could aggravate residual enzymatic deficits.

---

Symptoms

PHGDH deficiency disrupts central nervous system development and function; symptoms span multiple domains:

1. Congenital Microcephaly
   A head circumference below the 3rd percentile at birth, reflecting impaired brain growth en.wikipedia.org.

2. Psychomotor Retardation
   Failure to achieve developmental milestones such as sitting or walking.

3. Refractory Seizures
   Often myoclonic or tonic–clonic, beginning in infancy and resistant to standard anticonvulsants pmc.ncbi.nlm.nih.gov.

4. Intellectual Disability
   Ranges from moderate to severe, depending on residual serine synthesis.

5. Behavioral Disorders
   Hyperactivity, agitation, or autistic-like behaviors.

6. Hypotonia
   Decreased muscle tone leads to floppy posture and poor head control.

7. Spasticity
   Increased muscle tone and exaggerated reflexes in some juvenile cases.

8. Ataxia
   Unsteady gait and poor coordination in older children and adults.

9. Failure to Thrive
   Poor weight gain and growth due to metabolic stress.

10. Feeding Difficulties
    Poor suck and swallow coordination in neonates.

11. Ocular Abnormalities
    Strabismus or nystagmus from CNS involvement.

12. Sensorineural Hearing Loss
    Damage to auditory pathways in the brain.

13. Peripheral Neuropathy
    Numbness, tingling, or neuropathic pain in limbs in adult form medlineplus.gov.

14. Microphthalmia
    Small eyes, especially in Neu-Laxova syndrome.

15. Ichthyosis
    Dry, scaly skin in severe neonatal presentations.

16. Joint Contractures
    Fixed flexion of elbows or knees in Neu-Laxova syndrome.

17. Hydrops Fetalis
    Generalized edema detectable on prenatal ultrasound.

18. Metabolic Acidosis
    Due to accumulation of upstream metabolites and impaired serine catabolism.

19. Hypoglycemia
    Occasionally seen during intercurrent illness.

20. Growth Hormone Axis Dysfunction
    Secondary endocrine abnormalities contributing to short stature.

---

Diagnostic Tests

Physical Examination

1. Head Circumference Measurement
   Quantifies microcephaly against age-matched norms.

2. General Observation
   Assesses feeding, breathing, and skin (for ichthyosis).

3. Neurological Exam
   Evaluates tone, reflexes, and coordination.

4. Growth Assessment
   Plots height and weight on growth charts.

5. Muscle Tone Assessment
   Distinguishes hypotonia from spasticity.

6. Craniofacial Examination
   Checks for dysmorphic features like microphthalmia.

7. Joint Range of Motion
   Detects contractures in severe forms.

8. Behavioral Screening
   Early autism and hyperactivity scales.

Manual (Developmental) Tests

9. Bayley Scales of Infant Development
   Standardized motor and cognitive assessment.

10. Denver Developmental Screening Test
    Quick screen of gross motor and language.

11. Gross Motor Function Measure
    Evaluates changes over time in mobility.

12. Romberg Test
    Checks proprioception and balance.

13. Finger–Nose Test
    Assesses cerebellar coordination.

14. Heel-to-Shin Test
    Another cerebellar function measure.

15. Manual Muscle Testing
    Grades limb strength on a 0–5 scale.

16. Sensory Examination
    Pinprick and vibration sense testing.

Lab & Pathological Tests

17. Plasma Amino Acid Analysis
    Low serine levels confirm biochemical defect medlineplus.gov.

18. CSF Amino Acid Analysis
    More specific for CNS serine deficiency.

19. Urine Organic Acids
    Elevated upstream metabolites (3-phosphoglycerate).

20. PHGDH Enzyme Assay
    Measures activity in cultured fibroblasts.

21. Genetic Testing (PHGDH Sequencing)
    Identifies pathogenic variants.

22. Complete Metabolic Panel
    Evaluates liver and kidney function.

23. Blood Gas Analysis
    Detects metabolic acidosis.

24. Lactate Measurement
    Helps rule out mitochondrial disorders.

Electrodiagnostic Tests

25. Electroencephalogram (EEG)
    Characterizes seizure types and guides therapy.

26. Electromyography (EMG)
    Assesses peripheral neuropathy in adults.

27. Nerve Conduction Studies
    Measures speed and amplitude of nerve signals.

28. Somatosensory Evoked Potentials (SEP)
    Tests sensory pathway integrity.

29. Visual Evoked Potentials (VEP)
    Screens for optic pathway delay.

30. Brainstem Auditory Evoked Responses (BAER)
    Checks hearing pathways objectively.

31. Blink Reflex Testing
    Cranial nerve function.

32. Sleep EEG (Polysomnography)
    In infants with refractory seizures.

Imaging Tests

33. Brain MRI
    Reveals cortical atrophy, delayed myelination.

34. CT Scan of Head
    Detects calcifications or structural anomalies.

35. MR Spectroscopy
    Shows reduced serine peaks in brain tissue.

36. Ultrasound (Prenatal Brain)
    Detects hydrops and microcephaly in utero.

37. Diffusion Tensor Imaging (DTI)
    Evaluates white matter integrity.

38. Spine MRI
    Screens for associated anomalies in severe syndromes.

39. Skeletal Survey
    In Neu-Laxova syndrome for limb contractures.

40. PET-CT Brain Metabolism Scan
    Shows hypometabolism in affected regions.

Non-Pharmacological Treatments

Non-drug strategies aim to support neurodevelopment, optimize function, and enhance quality of life. They fall into four categories: physiotherapy/electrotherapy, exercise, mind-body, and educational self-management.

Physiotherapy & Electrotherapy

1. Neurodevelopmental Treatment (NDT)

   • Description: Hands-on, individualized approach to facilitate normal movement patterns in infants and children.

   • Purpose: Improve motor control, posture, and functional mobility.

   • Mechanism: Therapist uses guided handling to inhibit abnormal muscle tone and promote alignment, enhancing neural plasticity through repetitive practice.

2. Constraint-Induced Movement Therapy (CIMT)

   • Description: Restricting the patient’s less-affected limb to encourage use of the weaker side.

   • Purpose: Strengthen and improve motor function in hemiparetic limbs.

   • Mechanism: Forcing use of the affected side drives cortical reorganization, boosting motor cortex representation.

3. Transcutaneous Electrical Nerve Stimulation (TENS)

   • Description: Low-voltage electrical stimulation applied via skin electrodes.

   • Purpose: Reduce pain, improve sensory feedback, and facilitate muscle contraction.

   • Mechanism: Stimulates Aβ fibers to inhibit pain signals (gate control theory) and activate muscle fibers.

4. Functional Electrical Stimulation (FES)

   • Description: Electrical currents applied to motor nerves to elicit muscle contractions.

   • Purpose: Improve gait, prevent contractures, and maintain muscle mass.

   • Mechanism: Electrically induced contractions mimic voluntary movement, promoting neural and muscular strengthening.

5. Hydrotherapy (Aquatic Therapy)

   • Description: Therapeutic exercises performed in warm water pools.

   • Purpose: Enhance mobility, reduce spasticity, and provide resistance training with buoyancy support.

   • Mechanism: Warm water relaxes muscles; buoyancy reduces weight-bearing, enabling safer movement and strengthening.

6. Bobath Concept

   • Description: Holistic therapy emphasizing individualized, functional activities.

   • Purpose: Reduce abnormal tone, facilitate normal movement patterns.

   • Mechanism: Therapist-guided rotations and alignments recalibrate proprioceptive feedback loops.

7. Proprioceptive Neuromuscular Facilitation (PNF)

   • Description: Stretching and strengthening techniques using diagonal movement patterns.

   • Purpose: Increase range of motion and muscular coordination.

   • Mechanism: Combines isotonic and isometric contractions with stretching to activate proprioceptors.

8. Vibration Therapy

   • Description: High-frequency mechanical oscillations applied to muscles or platforms.

   • Purpose: Reduce spasticity, enhance muscle activation.

   • Mechanism: Stimulates muscle spindles, increasing Ia afferent input to modulate tone.

9. Mirror Therapy

   • Description: Using a mirror to create a visual illusion of movement in the affected limb.

   • Purpose: Improve motor function and reduce neglect.

   • Mechanism: Visual feedback activates mirror neuron systems, promoting motor relearning.

10. Sensory Integration Therapy

    • Description: Activities that challenge vestibular, tactile, and proprioceptive systems.

    • Purpose: Enhance sensory processing and integration.

    • Mechanism: Repeated sensory experiences refine neural circuits responsible for processing sensory inputs.

11. Electromyographic Biofeedback (EMG-BFB)

    • Description: Visual/audio feedback of muscle activation levels.

    • Purpose: Teach voluntary control of specific muscles.

    • Mechanism: Real-time feedback reinforces correct activation patterns, guiding neuroplastic changes.

12. Vestibular Stimulation

    • Description: Motion-based activities (e.g., swings, balance boards).

    • Purpose: Improve balance, spatial orientation, and postural control.

    • Mechanism: Stimulates vestibular apparatus, enhancing vestibulospinal reflexes.

13. Deep Pressure Therapy

    • Description: Firm, sustained pressure applied to joints and muscles (e.g., weighted blankets).

    • Purpose: Reduce anxiety and hyperactivity.

    • Mechanism: Activates mechanoreceptors, releasing serotonin and balancing autonomic tone.

14. Neuromuscular Electrical Stimulation (NMES)

    • Description: Pulsed electrical currents to elicit muscle contractions.

    • Purpose: Prevent atrophy and strengthen weak muscles.

    • Mechanism: Depolarizes motor neurons, reinforcing muscle fiber recruitment.

15. Therapeutic Ultrasound

    • Description: High-frequency sound waves applied to soft tissues.

    • Purpose: Reduce pain, promote tissue healing.

    • Mechanism: Mechanical vibrations increase tissue temperature and cellular activity, improving blood flow.

Exercise Therapies

1. Strength Training

   • Targets weak muscle groups through progressive resistance exercises, enhancing functional mobility.

2. Balance & Coordination Drills

   • Uses stability balls, wobble boards to improve proprioception and prevent falls.

3. Aerobic Exercise

   • Low-impact activities (e.g., stationary cycling) boost cardiovascular health and neurogenesis.

4. Gait Training

   • Treadmill or overground practice with or without body-weight support to refine walking patterns.

5. Flexibility Stretching

   • Static and dynamic stretches reduce contractures and maintain joint range.

Mind-Body Approaches

1. Yoga

   • Combines stretching, balance poses, and breath control to enhance physical and mental well-being.

2. Tai Chi

   • Slow, flowing movements improve balance, coordination, and stress reduction.

3. Guided Imagery

   • Mental visualization techniques to reduce anxiety and pain perception.

4. Meditation & Mindfulness

   • Focused attention and breath awareness lower stress and modulate pain pathways.

5. Music Therapy

   • Rhythmic and melodic interventions to improve mood, coordination, and social engagement.

Educational Self-Management

1. Patient & Caregiver Training

   • Workshops on positioning, safe transfers, and seizure management empower families.

2. Home Exercise Programs

   • Personalized routines ensure consistency and carryover of therapeutic gains.

3. Assistive Device Education

   • Instruction on orthoses, mobility aids to maximize independence.

4. Nutrition & Lifestyle Coaching

   • Guidance on balanced diets and sleep hygiene to support overall health.

5. Seizure Action Plans

   • Written protocols for recognizing and responding to seizure emergencies.

---

Pharmacological Treatments

Medication aims to manage seizures, spasticity, and metabolic derangements. Dosages reflect pediatric norms but must be individualized.

1. L-Serine Supplementation

   • Class: Amino acid

   • Dosage: 100–400 mg/kg/day in divided doses

   • Timing: With meals

   • Side Effects: Gastrointestinal upset, rare hypersensitivity

   • Notes: Restores serine levels, improving neurologic outcomes.

2. Glycine

   • Class: Amino acid co-substrate

   • Dosage: 100 mg/kg/day

   • Timing: TID

   • Side Effects: Drowsiness, gastrointestinal discomfort

   • Notes: Supports downstream neurotransmitter balance.

3. Diazepam

   • Class: Benzodiazepine (antiseizure)

   • Dosage: 0.1–0.3 mg/kg IV/PO

   • Timing: PRN seizures

   • Side Effects: Sedation, respiratory depression

4. Clobazam

   • Class: Benzodiazepine

   • Dosage: 0.5 mg/kg/day

   • Timing: BID

   • Side Effects: Ataxia, irritability

5. Levetiracetam

   • Class: SV2A modulator

   • Dosage: 20–60 mg/kg/day

   • Timing: BID

   • Side Effects: Behavioral changes, somnolence

6. Valproic Acid

   • Class: Broad-spectrum anticonvulsant

   • Dosage: 20–40 mg/kg/day

   • Timing: BID–TID

   • Side Effects: Hepatotoxicity, weight gain

7. Topiramate

   • Class: Anticonvulsant

   • Dosage: 5–9 mg/kg/day

   • Timing: BID

   • Side Effects: Cognitive slowing, nephrolithiasis

8. Baclofen

   • Class: GABA_B agonist (antispasticity)

   • Dosage: 0.5–2 mg/kg/day

   • Timing: TID

   • Side Effects: Muscle weakness, sedation

9. Tizanidine

   • Class: α2-agonist

   • Dosage: 0.05 mg/kg/dose

   • Timing: TID

   • Side Effects: Hypotension, dry mouth

10. Gabapentin

    • Class: Calcium channel modulator

    • Dosage: 10–20 mg/kg/day

    • Timing: TID

    • Side Effects: Dizziness, ataxia

11. Oxcarbazepine

    • Class: Sodium channel blocker

    • Dosage: 10–30 mg/kg/day

    • Timing: BID

    • Side Effects: Hyponatremia, rash

12. Rufinamide

    • Class: Triazole anticonvulsant

    • Dosage: 20–45 mg/kg/day

    • Timing: BID

    • Side Effects: Somnolence, nausea

13. Lamotrigine

    • Class: Sodium channel blocker

    • Dosage: 1–10 mg/kg/day

    • Timing: BID

    • Side Effects: Rash (Stevens-Johnson risk)

14. Benzodiazepine Rescue Kits

    • Class: Anxiolytic/antiseizure

    • Dosage: Per weight-based protocols

    • Timing: Emergency use

    • Side Effects: Sedation

15. Vitamin B6 (Pyridoxine)

    • Class: Cofactor supplement

    • Dosage: 50–100 mg/day

    • Timing: Daily

    • Side Effects: Rare neuropathy

16. Vitamin B12

    • Class: Cofactor

    • Dosage: 25–50 mcg/day

    • Timing: Daily

    • Side Effects: Minimal

17. Folic Acid

    • Class: Cofactor

    • Dosage: 0.4–1 mg/day

    • Timing: Daily

    • Side Effects: Rare GI discomfort

18. Thiamine

    • Class: Cofactor

    • Dosage: 25–100 mg/day

    • Timing: Daily

    • Side Effects: Rare hypersensitivity

19. Clonazepam

    • Class: Benzodiazepine

    • Dosage: 0.01–0.1 mg/kg/day

    • Timing: BID

    • Side Effects: Sedation, tolerance

20. Phenobarbital

    • Class: Barbiturate

    • Dosage: 2–8 mg/kg/day

    • Timing: QHS (at night)

    • Side Effects: Cognitive impairment, sedation

---

Dietary Molecular Supplements

Adjunctive nutrients support cerebral metabolism and antioxidant defenses.

1. Docosahexaenoic Acid (DHA)

   • Dosage: 10–50 mg/kg/day

   • Function: Supports neuronal membrane fluidity and signaling

   • Mechanism: Incorporates into phospholipids, modulating receptor function

2. Eicosapentaenoic Acid (EPA)

   • Dosage: 5–30 mg/kg/day

   • Function: Anti-inflammatory, mood stabilization

   • Mechanism: Precursor to resolvins, reducing neuroinflammation

3. Alpha-Lipoic Acid

   • Dosage: 3–10 mg/kg/day

   • Function: Antioxidant, mitochondrial support

   • Mechanism: Regenerates glutathione, enhances ATP production

4. Coenzyme Q10

   • Dosage: 2–10 mg/kg/day

   • Function: Mitochondrial electron transport support

   • Mechanism: Facilitates ATP generation, scavenges free radicals

5. N-Acetylcysteine (NAC)

   • Dosage: 10–20 mg/kg/day

   • Function: Precursor to glutathione

   • Mechanism: Increases intracellular cysteine for antioxidant synthesis

6. Magnesium

   • Dosage: 5–10 mg/kg/day

   • Function: NMDA receptor modulation, seizure threshold support

   • Mechanism: Blocks excitotoxic calcium influx

7. Zinc

   • Dosage: 1–3 mg/kg/day

   • Function: Enzyme cofactor, neurotransmission

   • Mechanism: Stabilizes protein structures, modulates GABAergic activity

8. Vitamin D3

   • Dosage: 400–1000 IU/day

   • Function: Neuroprotection, bone health

   • Mechanism: Regulates neurotrophins, calcium homeostasis

9. Vitamin E (α-Tocopherol)

   • Dosage: 5–15 mg/kg/day

   • Function: Lipid antioxidant

   • Mechanism: Interrupts lipid peroxidation in cell membranes

10. Choline

    • Dosage: 10 mg/kg/day

    • Function: Precursor for acetylcholine and phosphatidylcholine

    • Mechanism: Supports neurotransmission and membrane integrity

---

Specialized Drug Therapies

Advanced agents targeting bone health, regeneration, and viscoelastic support.

1. Alendronate (Bisphosphonate)

   • Dosage: 5 mg/day or 35 mg/week

   • Function: Inhibit osteoclast-mediated bone resorption

   • Mechanism: Binds hydroxyapatite, induces osteoclast apoptosis

2. Zoledronic Acid

   • Dosage: 5 mg IV annually

   • Function: Potent bisphosphonate for bone density support

   • Mechanism: Inhibits farnesyl pyrophosphate synthase, disrupting osteoclast function

3. Platelet-Rich Plasma (Regenerative)

   • Dosage: Autologous injection 2–4 mL per site

   • Function: Promote tissue repair via growth factors

   • Mechanism: Releases PDGF, TGF-β, VEGF to stimulate healing

4. Autologous Conditioned Serum

   • Dosage: 2–4 mL injections weekly × 3–6

   • Function: Anti-inflammatory cytokine delivery

   • Mechanism: Elevates IL-1 receptor antagonist to reduce joint inflammation

5. Hyaluronic Acid (Viscosupplementation)

   • Dosage: 20 mg intra-articular weekly × 3–5

   • Function: Restore synovial fluid viscosity

   • Mechanism: Enhances lubrication, reduces cartilage shear forces

6. Cross-Linked Hyaluronate

   • Dosage: 60 mg single injection

   • Function: Prolonged joint cushioning

   • Mechanism: High-molecular-weight gel resists enzymatic degradation

7. Mesenchymal Stem Cells (MSC)

   • Dosage: 1–10×10^6 cells per injection

   • Function: Regenerate neural and musculoskeletal tissues

   • Mechanism: Differentiate into targeted cell lineages and secrete trophic factors

8. Neural Stem Cells

   • Dosage: Experimental protocols vary

   • Function: Replace or support damaged neurons

   • Mechanism: Integrate into neural circuits, releasing neurotrophins

9. Bone Marrow Aspirate Concentrate

   • Dosage: 5–10 mL concentrate per site

   • Function: Autologous regenerative therapy

   • Mechanism: Delivers progenitor cells and growth factors

10. Recombinant Human Growth Hormone

    • Dosage: 0.025–0.05 mg/kg/day

    • Function: Support growth and neural repair

    • Mechanism: Stimulates IGF-1 production, enhancing tissue growth

---

Surgical Interventions

When conservative and pharmacological measures fail, surgery may address complications.

1. Cranial Vault Remodeling

   • Procedure: Surgical reshaping of skull bones to relieve pressure.

   • Benefits: Reduces intracranial hypertension, improves head shape.

2. Corpus Callosotomy

   • Procedure: Partial or complete severing of corpus callosum.

   • Benefits: Decreases drop attacks and generalized seizures.

3. Vagal Nerve Stimulation (VNS)

   • Procedure: Implantation of electrode on vagus nerve.

   • Benefits: Reduces seizure frequency and severity.

4. Deep Brain Stimulation (DBS)

   • Procedure: Electrodes placed in thalamus or basal ganglia.

   • Benefits: Modulates pathological neuronal circuits, decreases refractory seizures.

5. Intrathecal Baclofen Pump

   • Procedure: Catheter delivers baclofen directly into CSF.

   • Benefits: Improves spasticity control with lower systemic doses.

6. Selective Dorsal Rhizotomy

   • Procedure: Sectioning sensory nerve roots in spinal cord.

   • Benefits: Reduces lower-limb spasticity, improves gait.

7. Orthopedic Tendon Release

   • Procedure: Lengthening of tight tendons (e.g., Achilles).

   • Benefits: Increases range of motion, reduces contractures.

8. Nerve Transfers

   • Procedure: Redirect functioning nerves to reinnervate paralyzed muscles.

   • Benefits: Restores voluntary movement.

9. Intracranial Electrodes for Seizure Mapping

   • Procedure: Implant grid electrodes to localize seizure focus.

   • Benefits: Guides resective surgery with precision.

10. Epilepsy Resection Surgery

    • Procedure: Removal of epileptogenic brain tissue.

    • Benefits: Potentially curative for focal seizures.

---

 Prevention Strategies

Although genetic, optimizing prenatal and early-life care can mitigate severity.

1. Carrier Screening for PHGDH mutations in at-risk populations.

2. Prenatal Genetic Counseling to inform reproductive choices.

3. Early Newborn Metabolic Screening where available.

4. Periconceptional Folic Acid supplementation to support neurodevelopment.

5. Optimized Maternal Nutrition rich in serine precursors.

6. Avoidance of Neurotoxins (alcohol, drugs) during pregnancy.

7. Early Intervention Programs for infants with delayed milestones.

8. Regular Developmental Surveillance to initiate therapies promptly.

9. Immunizations to prevent CNS infections.

10. Environmental Enrichment to stimulate neural plasticity.

---

When to See a Doctor

Prompt evaluation is crucial if an infant or child presents with:

• Persistent seizures or unusual movements

• Delayed head control or microcephaly

• Hypotonia or spasticity

• Feeding difficulties or failure to thrive

• Developmental delays (motor, speech)

---

“Do’s” & “Don’ts”

Do:

1. Ensure consistent L-serine supplementation.

2. Adhere to prescribed physiotherapy routines.

3. Monitor seizure logs and medication side effects.

4. Maintain a seizure-safe environment.

5. Engage in family education sessions.

6. Optimize nutrition with supportive supplements.

7. Encourage gentle play and sensory activities.

8. Keep regular neurology follow-ups.

9. Document developmental milestones.

10. Use assistive devices properly.

Don’t:

1. Skip or alter medication dosages without consulting a physician.

2. Expose the child to high-risk seizure triggers (flashing lights).

3. Overlook signs of medication toxicity (e.g., sedation).

4. Neglect wound or skin care around orthoses.

5. Discontinue therapies when progress seems slow.

6. Compound seizures with sleep deprivation.

7. Rely on unproven “miracle cures.”

8. Ignore behavioral changes or mood swings.

9. Underestimate the importance of hydration.

10. Delay genetic counseling in future pregnancies.

---

Frequently Asked Questions

1. What causes D-glycerate dehydrogenase deficiency?
   It’s caused by mutations in the PHGDH gene, inherited in an autosomal recessive pattern.

2. How is it diagnosed?
   Diagnosis involves plasma amino acid analysis showing low serine, genetic testing for PHGDH variants, and sometimes enzyme assay in fibroblasts.

3. Can dietary serine cure the condition?
   Supplementation improves metabolic balance and may reduce seizures but cannot fully reverse established neurological damage.

4. Is there newborn screening?
   It is not part of most standard panels but may be included in expanded metabolic screening programs.

5. What is the prognosis?
   Early treatment correlates with better motor and cognitive outcomes; severity varies from mild delay to profound disability.

6. Are siblings at risk?
   Siblings have a 25% chance of being affected if both parents are carriers.

7. Can adults have milder forms?
   Rare mild phenotypes present later with movement disorders or psychiatric symptoms.

8. Are there clinical trials?
   Trials of novel enzyme replacement and gene therapy are in early phases.

9. How often should therapy be performed?
   Daily home exercises plus weekly to biweekly clinic sessions optimize gains.

10. What specialists are involved?
    A multidisciplinary team includes neurologists, metabolic specialists, physiotherapists, dietitians, and genetic counselors.

11. Can seizures be controlled fully?
    Many achieve significant reduction, but some remain refractory requiring advanced therapies.

12. Is gene therapy possible?
    Preclinical gene replacement approaches show promise but await human trials.

13. What side effects come from serine treatment?
    Mostly gastrointestinal issues; long-term safety is generally favorable.

14. How to support family caregivers?
    Through respite services, support groups, and education programs.

15. When is surgery indicated?
    For refractory seizures (e.g., corpus callosotomy) or spasticity not responsive to medications.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: June 23, 2025.

PDF Document For This Disease Conditions

References